{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T12:23:31Z","timestamp":1789302211733,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CP\/CPPS is characterized by pain, the primary symptom, which significantly affects QoL and disrupts lower urinary tract function. Conventional monotherapies are often ineffective, necessitating multimodal treatments targeting key symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, prospective, randomized, parallel, positive-controlled trial enrolled 323 men aged 18\u201360\u00a0years with CP\/CPPS across 14 centers in China. Participants were randomly assigned to three groups: tamsulosin 0.2\u00a0mg daily, Ningmitai capsule (NMT) 1.52\u00a0g thrice daily, or a combination of both, for 8\u00a0weeks. The primary endpoint was the change in the total NIH-CPSI score from baseline to week 8. Secondary endpoints included changes in pain, urinary, QoL subdomains, the percentage of patients achieving a \u226525% reduction in NIH-CPSI total score, and pain scores. Safety was monitored through adverse events and liver function tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 323 patients, 108 received tamsulosin, 109 NMT, and 106 combination therapy. After 8\u00a0weeks, both NMT and combination therapy demonstrated significantly greater reductions in total NIH-CPSI scores compared to tamsulosin (\u221211.44 vs. \u22128.58,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001; \u221211.94 vs. \u22128.58,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Combination therapy also significantly reduced pain (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001) and improved QoL (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) compared to tamsulosin. The NMT group showed greater improvements in pain scores at both 4 and 8\u00a0weeks compared to tamsulosin (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). At week 8, the percentage of patients achieving a \u226525% reduction in NIH-CPSI total score was significantly higher in the NMT (78.64% vs. 55.91%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) and combination groups (82.83% vs. 55.91%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Subgroup analyses indicated that NMT was most effective in patients with mild to moderate CP\/CPPS, younger age (18\u201334\u00a0years), and disease duration of &amp;lt;12\u00a0months. No serious adverse events occurred, and NMT was well-tolerated across all groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NMT demonstrated superior efficacy over tamsulosin in reducing pain and improving QoL in CP\/CPPS patients. Combination therapy provided enhanced symptom relief, particularly in micturition and QoL domains, supporting a multimodal approach for more effective CP\/CPPS management. These findings validate NMT as a promising treatment, either alone or in combination, for CP\/CPPS. Further long-term studies are needed to optimize its use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , identifier NCT05890235.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1667819","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:32:10Z","timestamp":1764743530000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Ningmitai capsule in patients with chronic prostatitis\/chronic pelvic pain syndrome: a multicenter, prospective, randomized, parallel, positive-controlled study"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingjing","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunli","family":"Men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaozhao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.7326\/0003-4819-141-8-200410190-00005","article-title":"Ciprofloxacin or tamsulosin in men with chronic prostatitis\/chronic pelvic pain syndrome: a randomized, double-blind trial","volume":"141","author":"Alexander","year":"2004","journal-title":"Ann. Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1001\/archinte.163.20.2433","article-title":"Depression and pain comorbidity: a literature review","volume":"163","author":"Bair","year":"2003","journal-title":"Arch. Intern Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"100852","DOI":"10.1016\/j.conctc.2021.100852","article-title":"Comparing pregabalin and gabapentin for persistent neuropathic pain: a protocol for a pilot N-of-1 trial series","volume":"24","author":"Bashford","year":"2021","journal-title":"Contemp. Clin. Trials Commun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12894-017-0223-5","article-title":"The role of flower pollen extract in managing patients affected by chronic prostatitis\/chronic pelvic pain syndrome: a comprehensive analysis of all published clinical trials","volume":"17","author":"Cai","year":"2017","journal-title":"BMC Urol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00345-010-0537-3","article-title":"Effects of a 6-month course of tamsulosin for chronic prostatitis\/chronic pelvic pain syndrome: a multicenter, randomized trial","volume":"29","author":"Chen","year":"2011","journal-title":"World J. Urol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5847806","DOI":"10.1155\/2020\/5847806","article-title":"The anti-inflammatory and antioxidative effects of ningmitai capsule in the experimental autoimmune prostatitis rat model","volume":"2020","author":"Chen","year":"2020","journal-title":"Evid-Based Complement. Altern. Med. ECAM"},{"key":"B7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.eururo.2009.08.020","article-title":"EAU guidelines on chronic pelvic pain","volume":"57","author":"Fall","year":"2010","journal-title":"Eur. Urol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"CD012552","DOI":"10.1002\/14651858.CD012552.pub2","article-title":"Pharmacological interventions for treating chronic prostatitis\/chronic pelvic pain syndrome","volume":"10","author":"Franco","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1464-410X.2008.07493.x","article-title":"The concept of neurogenic inflammation","volume":"101","author":"Geppetti","year":"2008","journal-title":"BJU Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"953205","DOI":"10.3389\/fphar.2022.953205","article-title":"Best practice in the chemical characterisation of extracts used in pharmacological and toxicological research\u2014The ConPhyMP\u2014Guidelines12","volume":"13","author":"Heinrich","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2494550","DOI":"10.1080\/13685538.2025.2494550","article-title":"Prostatitis and male infertility","volume":"28","author":"Hua","year":"2025","journal-title":"Aging Male Off. J. Int. Soc. Study Aging Male"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e11840","DOI":"10.1097\/MD.0000000000011840","article-title":"Meta-analysis of the efficacy of ningmitai capsule on the treatment of chronic prostatitis in China","volume":"97","author":"Jin","year":"2018","journal-title":"Med. Baltim."},{"key":"B13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5213\/inj.2011.15.2.92","article-title":"Tamsulosin monotherapy versus combination therapy with antibiotics or anti-inflammatory agents in the treatment of chronic pelvic pain syndrome","volume":"15","author":"Kim","year":"2011","journal-title":"Int. Neurourol. J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/JU.0000000000004564","article-title":"Male chronic pelvic pain: AUA guideline: part I evaluation and management approach","volume":"214","author":"Lai","year":"","journal-title":"J. Urol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/JU.0000000000004565","article-title":"Male chronic pelvic pain: AUA guideline: part II treatment of chronic prostatitis\/chronic pelvic pain syndrome","volume":"214","author":"Lai","year":"","journal-title":"J. Urol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.juro.2009.04.011","article-title":"The prevalence of prostatitis-like symptoms in China","volume":"182","author":"Liang","year":"2009","journal-title":"J. Urol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s0022-5347(05)68562-x","article-title":"The national institutes of health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic prostatitis collaborative research network","volume":"162","author":"Litwin","year":"1999","journal-title":"J. Urol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"949316","DOI":"10.3389\/fphar.2022.949316","article-title":"Ningmitai capsules have anti-inflammatory and pain-relieving effects in the chronic prostatitis\/chronic pelvic pain syndrome mouse model through systemic immunity","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"qfaf024","DOI":"10.1093\/sexmed\/qfaf024","article-title":"The efficacy of combination therapy with ningmitai capsule and sildenafil in men with chronic prostatitis\/chronic pelvic pain syndrome and erectile dysfunction: a prospective, multicenter, randomized controlled trial","volume":"13","author":"Luo","year":"2025","journal-title":"Sex. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1277243","DOI":"10.3389\/fimmu.2023.1277243","article-title":"Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy","volume":"14","author":"Miao","year":"2023","journal-title":"Front. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"953403","DOI":"10.3389\/fimmu.2022.953403","article-title":"Metabolomics analysis reveals the differential metabolites and establishes the therapeutic effect prediction nomogram among CP\/CPPS patients who respond or do not respond to LiST","volume":"13","author":"Meng","year":"2022","journal-title":"Front. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/s0090-4295(03)00583-1","article-title":"Levofloxacin for chronic prostatitis\/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial","volume":"62","author":"Nickel","year":"2003","journal-title":"Urology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/j.1464-410X.2003.04766.x","article-title":"A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for Male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis)","volume":"93","author":"Nickel","year":"2004","journal-title":"BJU Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1056\/NEJMoa0803240","article-title":"Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome","volume":"359","author":"Nickel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"7754876","DOI":"10.1155\/2023\/7754876","article-title":"Acupuncture for chronic prostatitis or chronic pelvic pain syndrome: an updated systematic review and meta-analysis","volume":"2023","author":"Pan","year":"2023","journal-title":"Pain Res. Manag."},{"key":"B26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40266-021-00890-2","article-title":"Diagnostic and management strategies for patients with chronic prostatitis and chronic pelvic pain syndrome","volume":"38","author":"Pena","year":"2021","journal-title":"Drugs Aging"},{"key":"B27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/pcan.2016.8","article-title":"Chronic prostatitis\/chronic pelvic pain syndrome: a review of evaluation and therapy","volume":"19","author":"Polackwich","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11136-005-1317-1","article-title":"Responsiveness of the national institutes of health chronic prostatitis symptom index (NIH-CPSI)","volume":"15","author":"Propert","year":"2006","journal-title":"Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil."},{"key":"B29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00120-002-0286-z","article-title":"Four-glass or two glass test for chronic prostatitis","volume":"42","author":"Seiler","year":"2003","journal-title":"Urol. Ausg A"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/nau.70103","article-title":"Interstitial cystitis\/bladder pain syndrome in men","author":"Snipes","year":"2025","journal-title":"Neurourol. Urodyn"},{"key":"B31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41391-022-00559-w","article-title":"Low quality of life in men with chronic prostatitis-like symptoms","volume":"25","author":"Sugimoto","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.7326\/M21-1814","article-title":"Efficacy of acupuncture for chronic prostatitis\/chronic pelvic pain syndrome: a randomized trial","volume":"174","author":"Sun","year":"2021","journal-title":"Ann. Intern Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/luts.12477","article-title":"The efficacy of antibiotic and alpha-blocker combination therapy versus antibiotic monotherapy in chronic prostatitis\/chronic pelvic pain syndrome: a systematic review","volume":"15","author":"Widia","year":"2023","journal-title":"Low. Urin Tract. Symptoms"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e16136","DOI":"10.1097\/MD.0000000000016136","article-title":"Traditional Chinese medicine on treating chronic prostatitis\/chronic pelvic pain syndrome: a systematic review and meta-analysis","volume":"98","author":"Xue","year":"2019","journal-title":"Med. Baltim."},{"key":"B35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11934-023-01150-z","article-title":"Prostatitis: a review","volume":"24","author":"Yebes","year":"2023","journal-title":"Curr. Urol. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11934-018-0841-9","article-title":"Management of chronic prostatitis (CP)","volume":"19","author":"Zaidi","year":"2018","journal-title":"Curr. Urol. Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1557988320903200","DOI":"10.1177\/1557988320903200","article-title":"Chronic prostatitis\/chronic pelvic pain syndrome: a disease or symptom? Current perspectives on diagnosis, treatment, and prognosis","volume":"14","author":"Zhang","year":"2020","journal-title":"Am. J. Mens. Health"},{"key":"B38","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.urology.2021.01.018","article-title":"Efficacy and safety of ningmitai capsule in patients with chronic prostatitis\/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"153","author":"Zhang","year":"2021","journal-title":"Urology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1667819\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:32:10Z","timestamp":1764743530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1667819\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":38,"alternative-id":["10.3389\/fphar.2025.1667819"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1667819","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"article-number":"1667819"}}